Piperazine derivatives inhibiting human immunodeficiency virus replication

US6531476B1 · kind B1 · utility

Assignees

• Universite Paris 7—Denis Diderot 2 · FR
• COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES · FR

Inventors

• Francoise Heymans · Paris, FR
• Nathalie Dereuddre-Bosquet · Paris, FR
• Jean-Jacques Godfroid · Paris, FR
• Aazdine Lamouri · Bagneux, FR
• Pascal Clayette · Versailles, FR
• Marc Martin · Aubergenville, FR

Key dates

• Filing date: Mar 20, 2001
• Grant date: Mar 11, 2003
• Expiry date: Mar 20, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/18
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention concerns the use of a piperazine derivative of formula (I) wherein: A and B=C═O, C═S or CR7R8 with R7=H, methyl, cyano, cyanomethyl, CO2CH3 or (C═O)CH3 and R8=H or phenyl; R1 to R6=H, OH, or C1-C5 alkoxy; X represents: either C═O, O(C═O), O(C═S), O(SO2), NH(C═O), NH(C═S), NH(SO2), S(C═O) or S(C═S), then Y=NR9R10, CR9R10R11 in which R9, R10 and R11=H, C1-C5 alkyl, C2-C5 alkenyl, or C2-C5 alkynyl or Y=nitrogenous heterocycle comprising 5 to 10 atoms; or X represents O, S, O(C═O)O, NH(C═O)O, or S(C═O)O, then Y=CR9R10R11 with R9, R10, R11 as above; or one of its pharmaceutically acceptable salts for preparing a medicine inhibiting HIV. The invention is useful for treating HIV infection.